Patient Centric Monitoring: Preventing and Learning From Mistakes
When validating the 1,000,000 data points that compose the typical Phase III trial, focusing on errors that don’t matter easily leads to wasted resources. The industry’s initial response — risk based monitoring — more efficiently detects errors and risks, but can still expend resources on errors irrelevant to a trial’s validity and miss opportunities to detect and solve critical quality issues.
At ICON, we’ve drawn upon other industries’ methodologies for risk mitigation to evolve RBM into a more useful approach for protecting your clinical data. One of those methodologies, Human Factor Analysis (HFA), is employed by NASA, Ford, the U.S. EPA, major airlines, and several countries’ militaries to identify and mitigate human error in large, variously trained work forces. HFA uses uniquely structured datasets to reveal underlying behaviours and factors that are otherwise difficult for humans to sense or reconstruct, but ultimately are the root cause of an incident.
For example, take an airline that experienced several mid-air collisions. An HFA investigation, driven by datasets in which behaviours have been classified by analysis, may reveal that in most cases crashes are caused by a subset of miscommunications and gaps in teamwork among pilots and air traffic control. With an accurate understanding of the root cause of these crashes, airlines could mitigate risk by deploying tactical decision-making training or SOP adaptations that address the human errors that ultimately increased collision risk.
ICON has incorporated human factor analysis and into its risk based monitoring approach, which we call Patient Centric Monitoring. ICON’s information platform, ICONIK, systematically classifies and analyses the causes of trial errors to help CRAs deploy the right risk-mitigation resources to the sites that need them most.
![Patient-Centric-Monitoring Patient-Centric-Monitoring](https://icon.widen.net/content/gv24ivk8kg/web/Patient-Centric-Monitoring.png)
How does ICON use HFA to improve upon traditional RBM?
Let’s consider a site that has multiple issues with informed consent. A traditional monitoring approach would log a problem, potentially classify the site as high risk, and deploy general retraining on informed consent. ICON’s Patient Centric Monitoring draws upon HFA to instead look for trends in the centralised data, revealing that consent errors became more frequent after that site had enroled 100 or more patients. Upon CRA investigation, human factors analysis reveals that the issue was not a deficit in training, but in resources. To mitigate risk, the project team may limit the site to no more than 75 patients and provide additional investigator support focusing on resource allocation.
To identify deeper issues that could jeopardise trial integrity, such as protocol noncompliance, ICONIK transforms site data into visual analyses that enable smarter monitoring.
For example, in a clinical trial for which blood pressure (BP) is a measure of safety or efficacy, Patient Centric Monitoring utilises ICONIK’s real-time data to detect patterns that indicate problems with BP data collection. In the real trial data depicted in Figure 1, a lower-than-expected number of unique BP measurements (Figure 1a, black dots) revealed that some sites, including site 509 (Figure 1b), were deviating from the approved protocol by reporting rounded measurements.
An analysis for the human factors that led to the deviation revealed that the root problem was not a lack of training, but rather a technical issue with that site’s equipment. The BP meters automatically rounded BP values to the nearest 5 mmHg and, due to this being normal practice at the site, hospital staff did not know how to change the equipment settings. With this knowledge, ICON’s CRAs were then able to educate staff on how to change the device settings or replace the devices that could not be adapted, thereby preventing further error in this and future trials. With a traditional monitoring approach, the CRA would see the data and initiate site retraining without further investigation into the BP measurement distribution.
References:
1. Schuler, P., & Buckley, B. Re-Engineering Clinical Trials. pp 9-10. (Elsevier, London, 2015). Clara Heering
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel